Skip to main navigation Skip to search Skip to main content

Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAFV600 mutations: A cohort of the histology-independent VE-BASKET study

  • Noopur Raje
  • , Ian Chau
  • , David M. Hyman
  • , Vincent Ribrag
  • , Jean Yves Blay
  • , Josep Tabernero
  • , Elena Elez
  • , Jürgen Wolf
  • , Andrew J. Yee
  • , Martin Kaiser
  • , Heather Landau
  • , Jean Marie Michot
  • , Antoine Hollebecque
  • , Luisa Veronese
  • , Martina Makrutzki
  • , Bethany Pitcher
  • , Igor Puzanov
  • , Jose Baselga
  • Massachusetts General Hospital
  • Royal Marsden NHS Foundation Trust
  • Memorial Sloan-Kettering Cancer Center
  • Institut Gustave Roussy
  • Centre Léon Bérard
  • Vall d'Hebron Institute of Oncology
  • University of Cologne
  • F. Hoffmann-La Roche AG
  • F Hoffmann-La Roche

Research output: Contribution to journalArticlepeer-review

35 Scopus citations
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJCO Precision Oncology
Volume2
DOIs
StatePublished - 2018

Fingerprint

Dive into the research topics of 'Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAFV600 mutations: A cohort of the histology-independent VE-BASKET study'. Together they form a unique fingerprint.

Cite this